Q1 revenue ≥$2.50B (4%+ beat), Q2 FY27 guide ≥$2.65B (≥10% QoQ), non-GAAP GM ≥61%. Custom silicon revenue called out as 25%+ of DC, with named Maia + Arke contribution disclosed. Management explicitly addresses Trainium 3 status as 'on track' with concrete program detail.
Q1 revenue $2.40-2.50B (in-line to slight beat), Q2 FY27 guide $2.50-2.60B (4-8% QoQ). FY27 full-year guide reaffirmed at >$11B. Custom silicon commentary positive but no new design win disclosed. Trainium 3 referenced with continued 'working with AWS on multiple programs' language. CPO discussion remains defensive ('we participate via 3D SiPho').
Q1 revenue $2.35-2.40B (in-line on revenue but missed Street ~$2.44B), Q2 FY27 guide ≤$2.50B (≤5% QoQ). Management confirms 'partial Trainium 3 award' (not sole-source) OR non-GAAP GM falls to 58-59% on custom silicon mix. Management reaffirms FY27 >$11B but acceleration shifts to H2.
→ PRE-EARNINGS: Stock at $168 is extended (179% YoY, 57x fwd P/E, 19x P/S). Probability-weighted expected return into earnings is asymmetrically negative given setup. If holding from below, consider trimming 25-50% to lock gains; reinvestment of trimmed amount can wait for post-print clarity.
→ DO NOT add aggressively at $168 — base case 12-month target $124 implies ~26% downside even if base scenario plays out. Bull case $160 already breached.
→ If using options for asymmetric exposure: long straddle/strangle (~10-13% IV) is fair-priced but expensive; consider put credit spread $130/$120 to collect premium with bear-case cushion.
→ Pair trade idea: long AVGO / short MRVL into print as 'custom ASIC mean reversion' — AVGO at ~28x fwd vs MRVL at 57x fwd; if MRVL fades, AVGO benefits from cross-share rotation.
→ If Scenario 3-4 (miss/cut) plays out: defer adds until stock tests $128-145 zone (50DMA / base-case midpoint). DO NOT catch the knife at $150-160 — momentum traders will compound the de-rate.
→ If Scenario 1-2 (beat/in-line) plays out: hold existing position; only add on confirmed Maia + Arke revenue disclosure (Scenarios 5-7 acting as accelerants).
→ Watch list reads: LITE/COHR/CRDO as smaller-cap proxies — they typically move 1.5-2x MRVL's % move on AI infra catalysts. Use as 'beta amplifier' or 'tape risk' positions depending on direction.
→ Hedge against MRVL/NVDA same-week paired risk: MRVL prints May 27 AC, NVDA prints May 28 AM (~16 hours later). If MRVL beats but NVDA disappoints, MRVL gains can reverse Thu; if MRVL misses but NVDA beats, MRVL bounce is tradable Thursday AM.
Marvell Q1 FY27 revenue ≥ $2.40B (i.e., meets or beats guidance midpoint).
If below $2.40B → reduce position 50%+, expect 15%+ gap-down; do not add until $128-145 zone tested.
Marvell Q1 FY27 revenue beats Street consensus (~$2.44B) by 1%+ (i.e., ≥$2.465B).
Marvell Q2 FY27 revenue guidance is ≥ $2.55B (midpoint at or above consensus).
If <$2.50B → multi-quarter de-rate likely; expect stock to test 50DMA $128 within 5 trading days.
Non-GAAP gross margin prints at or above 60.0%.
Management discloses Microsoft Maia by name as a revenue-contributing program in Q1 FY27 (vs. 'ramping in CY26' generic language).
If named → reinforces diversification thesis; offsets in-line revenue with positive mix signal.
Management explicitly addresses Trainium 3 award status with new specific detail (units, revenue, program scope) beyond Q4 FY26 'working on Trainium 3/4' language.
If 'sole-source' explicitly stated → bull catalyst; if 'partial' or 'multi-vendor' explicitly stated → bear catalyst.
Marvell announces a 4th hyperscaler custom XPU design win during the Q1 FY27 call.
If announced → expect 5-8% additional upside on top of any base print reaction.
Marvell announces a commercial customer win for its own CPO (co-packaged optics) architecture during the Q1 FY27 call.
If announced → directly de-risks CPO displacement bear case; LITE/COHR mildly bearish read-through.
Stock closes May 28, 2026 (T+1 to print) BELOW $165.00 (i.e., setup risk dominates upside on stretched valuation).
Embeds same-week NVDA print risk — if both MRVL and NVDA underwhelm, AI-infra sympathy de-rate likely.
Stock closes May 28, 2026 (T+1 to print) ABOVE $185.00 (i.e., strong beat-raise breakout).
FY27 full-year revenue guidance is reaffirmed at >$11B (vs. cut to $10.0-10.5B).
If cut → bear-case activation; expect 25-35% downside over 1-2 weeks.
Management explicitly addresses NVIDIA Spectrum-6 Photonics CPO competition on the earnings call with offensive framing (e.g., 'our CPO wins are...') rather than defensive framing.
→ Positioning call was directionally WRONG: the thesis bet on 'stretched multiple → sell-the-news at $168' (P9 conf 0.55 sub-$165; P10 only 0.15 above-$185). Stock closed $204.83. Lesson: a stretched multiple is not a catalyst — a strong beat-raise on an accelerating AI-infra name can extend an already-extended setup.
→ Fundamental forecasts were sound: Q1 rev ≥$2.40B (✓), Q2 guide ≥$2.55B (✓), FY27 >$11B (✓). The one fundamental miss — non-GAAP GM <60% (58.9%) — was the correct bear mechanism (custom-silicon mix dilution) but immaterial to the stock.
→ No actionable new trade from this scoring: MRVL thesis already current (Hold, lastUpdated 2026-06-04). Event scored 9 days late; read-throughs already absorbed by the pipeline.